Test ID NIEM Niemann-Pick Type C Detection, Fibroblasts
Useful For
Diagnosis of Niemann-Pick disease type C
Additional Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
FIBR | Fibroblast Culture | Yes | Yes |
CRYOB | Cryopreserve for Biochem Studies | No | Yes |
Testing Algorithm
When this test is ordered, a fibroblast culture and cryopreservation for biochemical studies will always be performed at an additional charge. However, for multiple lysosomal enzyme assays on a patient utilizing fibroblast culture, only 1 culture is required regardless of the number of enzyme assays ordered. If viable cells are not obtained within 10 days, client will be notified.
Special Instructions
Method Name
NIEM: Radiolabeled Lipid Extraction Using Thin Layer Chromatography
CRYOB: Fibroblast Subculture Followed by Cryopreservation and Storage
Reporting Name
Niemann-Pick Type C, FibroSpecimen Type
TissueThis test is not recommended for prenatal testing.
Forms:
1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (T576) is available in Special Instructions.
2. If not ordering electronically, complete, print, and send a Neurology Test Request Form-General (T732) (http://www.mayomedicallaboratories.com/it-mmfiles/neurology-request-form.pdf)
Submit only 1 of the following specimens:
Specimen Type: Cultured fibroblasts
Container/Tube: T-75 or T-25 flask
Specimen Volume: 1 Full T-75 flask or 2 full T-25 flasks
Specimen Stability Information: Ambient (preferred)/Refrigerated <24 hours
Specimen Type: Skin biopsy
Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin. Tubes can be supplied upon request (Eagle's minimum essential medium with 1% penicillin and streptomycin [T115]).
Specimen Volume: 4-mm punch
Specimen Stability Information: Refrigerated (preferred)/Ambient
Specimen Minimum Volume
NA
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Tissue | Varies |
Clinical Information
Niemann-Pick disease type C (NPC)(1) is caused by a defect in cellular cholesterol trafficking that results in the accumulation of unesterified cholesterol in late endosomes/lysosomes. Age of onset is variable and ranges from the perinatal period to adulthood, and clinical presentation is also highly variable. Most individuals are diagnosed during childhood with symptoms including ataxia, vertical supranuclear gaze palsy, dystonia, progressive speech deterioration, and seizures resulting in death by the second or third decade of life. Infants may present with or without hepatosplenomegaly and respiratory failure. Those without liver and pulmonary disease may present with hypotonia and developmental delay. Adult-onset NPC is associated with a slower progression and is characterized by psychiatric illness, ataxia, dystonia, and speech difficulties.
The incidence of NPC is approximately 1 in 120,000 to 150,000 live births. NPC is an autosomal recessive condition and is caused by mutations in either the NPC1 or NPC2 genes. About 95% of individuals with NPC have mutations in the NPC1 gene. Mutations may also be identified in the NPC2 gene; see NPCMS / Niemann-Pick Type C, Full Gene Analysis.
Reference Values
If the results indicate that the patient's cultured fibroblasts esterify cholesterol at a level which is <10% of normal cultured fibroblasts and when filipin staining shows excessive storage of free cholesterol, it will be stated that the patient is positive for Niemann-Pick type C disease. All samples will be stained by filipin to see if a milder biochemical phenotype is the likely cause of the Niemann-Pick disease-like clinical picture.
Cautions
Biochemical testing is unreliable for Niemann-Pick disease type C carrier detection.
Day(s) Performed
Varies
Report Available
70-80 days depending on rapidity of growthPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
82658-Niemann-Pick type C detection
88233-Fibroblast culture
88240-Cryopreservation for biochemical studies